Celltrion
068270 · KOSPI · Biopharmaceuticals
About the company
Celltrion is a leading South Korean biopharmaceutical company specializing in the development and manufacturing of biosimilar and innovative biologics. The company has brought multiple biosimilar products to international markets, including Remsima (infliximab biosimilar), which was among the first biosimilars approved in the US and Europe. Celltrion operates its own manufacturing facilities in Incheon, South Korea.
| Exchange | KOSPI |
| Ticker | 068270 |
| Sector | Biopharmaceuticals |
| Indicative market cap USD | $9.50B |
| Website | Visit website |
Live quote
Loading live price…
| Market cap | |
| Day range | |
| 52-week range |
Where to buy
On its home market (KOSPI), it is accessible through global brokers that offer that exchange:
- Interactive Brokers — Direct access to 90+ markets worldwide, including many emerging exchanges.
- Saxo Bank — Multi-market access across Asia, Europe and the Middle East.
- Charles Schwab (Global) — Foreign ordinary shares on select markets; US-listed ADRs and ETFs.
- Fidelity International Trading — International stock trading on a number of developed and emerging markets.
- Korea Exchange — official exchange listing
Availability information only — not a recommendation or an offer to buy. Confirm eligibility, fees and current availability with your broker.
Other companies in South Korea
Company data and any live price are indicative, may be delayed or inaccurate, and are for research only — not investment advice. Verify with the exchange, the company's filings and your broker.